Home  |  Contact

UniProtKB/Swiss-Prot Q96SD1: Variant p.Gly118Val

Protein artemis
Gene: DCLRE1C
Variant information

Variant position:  118
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Valine (V) at position 118 (G118V, p.Gly118Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In RSSCID.
Any additional useful information about the variant.



Sequence information

Variant position:  118
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  692
The length of the canonical sequence.

Location on the sequence:   EASGEKEEIVVTLLPAGHCP  G SVMFLFQGNNGTVLYTGDFR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EASGEKEEIVVTLLPAGHCPGSVMFLFQGNNGTVLYTGDFR

Mouse                         EASGEKEEVVVTLLPAGHCPGSVMFLFQGSNGTVLYTGDFR

Rat                           EASGEKEEVVVTLLPAGHCPGSVMFLFQGSNGTVLYTGDFR

Chicken                       ETTGEKEDIEVTLLPAGHCPGSVMFLFQGENGTVLYTGDFR

Zebrafish                     ESTGETEDVVVTLLSAGHCPGSVMFLFEGAKGTVLYTGDFR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 692 Protein artemis
Alternative sequence 1 – 120 Missing. In isoform 2.
Alternative sequence 116 – 121 CPGSVM -> MKHQER. In isoform 3.
Mutagenesis 115 – 115 H -> A. Abolishes PRKDC-dependent endonuclease activity and V(D)J recombination.
Mutagenesis 136 – 136 D -> NA. Abolishes PRKDC-dependent endonuclease activity and V(D)J recombination.


Literature citations

Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow.
Noordzij J.G.; Verkaik N.S.; van der Burg M.; van Veelen L.R.; de Bruin-Versteeg S.; Wiegant W.; Vossen J.M.J.J.; Weemaes C.M.R.; de Groot R.; Zdzienicka M.Z.; van Gent D.C.; van Dongen J.J.M.;
Blood 101:1446-1452(2003)
Cited for: VARIANTS RSSCID VAL-118 AND GLU-135;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.